A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.
暂无分享，去创建一个
F. Hirsch | P. Bunn | W. Franklin | M. Varella‐Garcia | R. Dziadziuszko | F. Kabbinavar | D. Camidge | D. Sternberg | R. Martins | T. Eisen | F. Richardson | J. Rusk | K. Richardson | F. Schnell | B. Wacker | M. Varella-Garcia | D. Camidge | D. R. Camidge | F. Hirsch